公开(公告)号：US20200048350A1

公开(公告)日：2020-02-13

申请号：US16520293

申请日：2019-07-23

申请人： Inhibrx, Inc.

发明人： Brendan P. ECKELMAN ,  Michael D. KAPLAN ,  Katelyn M. WILLIS ,  Quinn DEVERAUX ,  Kyle S. JONES ,  Rajay A. PANDIT ,  John C. TIMMER

IPC分类号： C07K16/28

摘要： The invention relates generally to multispecific polypeptides that bind at least CD3, a second antigen, and a receptor of a T cell, such as a costimulatory receptor or an inhibitory receptor, in which the multispecific polypeptide constructs are able to engage CD3. In some embodiments, the multispecific polypeptide constructs bind a costimulatory receptor and provide costimulatory binding activity. In some embodiments, the multispecific polypeptide constructs bind an inhibitory receptor and block inhibitory activity. In some aspects, the multispecific polypeptides have constrained CD3 binding and bind to or engage CD3 only upon binding to the second antigen, such as a tumor associated antigen. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, result in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.

公开(公告)号：US20220162316A1

公开(公告)日：2022-05-26

申请号：US17524016

申请日：2021-11-11

申请人： InhibRx, Inc.

发明人： Rajay A. PANDIT ,  John C. Timmer ,  Angelica N. Sanabria ,  Florian Sulzmaier ,  Brendan P. Eckelman

IPC分类号： C07K16/28 ,  C07K16/30

摘要： Provided herein are binding polypeptides that specifically bind PD-1. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind PD-1. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided PD-1 binding polypeptides for treating diseases and conditions, such as cancer.